The estimated Net Worth of Noubar Afeyan is at least $1.82 Miliarda dollars as of 31 July 2024. Noubar Afeyan owns over 15,000 units of Moderna Inc stock worth over $176,831,433 and over the last 21 years he sold MRNA stock worth over $1,647,091,781. In addition, he makes $530,000 as Non-Executive Independent Chairman of the Board a Co-Founder at Moderna Inc.
Noubar has made over 87 trades of the Moderna Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of MRNA stock worth $1,799,400 on 31 July 2024.
The largest trade he's ever made was buying 8,888,888 units of Moderna Inc stock on 18 June 2019 worth over $19,999,998. On average, Noubar trades about 178,391 units every 16 days since 2004. As of 31 July 2024 he still owns at least 2,224,015 units of Moderna Inc stock.
You can see the complete history of Noubar Afeyan stock trades at the bottom of the page.
Dr. Noubar B. Afeyan Ph.D. serves as Non-Executive Independent Chairman of the Board, Co-Founder of the Company. Dr. Afeyan is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.
As the Non-Executive Independent Chairman of the Board a Co-Founder of Moderna Inc, the total compensation of Noubar Afeyan at Moderna Inc is $530,000. There are 11 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.
Noubar's mailing address filed with the SEC is 325 Vassar St Suite 1A, Cambridge, MA 02139, USA.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein a Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: